profit from every $100 of sales.
$0$100
Bausch Health Companies
$8.25-1.20% today
+18.9% in 1 year
1-year low $4.431-year high $8.91
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $19.67 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bausch Health Companies sold, what it kept, and what it did with the cash.
Sales went from $8.12 billion in 2022 to $10.3 billion in 2025, with $157 million of profit last year.
SalesProfit
Bausch Health Companies vs. similar companies
Bausch Health Companies grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bausch Health Companies | 19.7× · Fair price | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Bausch Health Companies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8,124 | 8,757 | 9,625 | 10,266 | |
| 5,760 | 6,198 | 6,843 | 7,253 | |
| 1,391 | 1,600 | 1,854 | 2,185 | |
| 2,729 | 2,202 | 2,822 | 3,179 | |
| -225 | -592 | -46 | 157 | |
| -0.62 | -1.62 | -0.13 | 0.42 | |
| 70.9% | 70.8% | 71.1% | 70.7% | |
| 17.1% | 18.3% | 19.3% | 21.3% | |
| -2.8% | -6.8% | -0.5% | 1.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25,686 | 27,350 | 26,523 | 26,366 |
| Cash | 564 | 947 | 1,181 | 1,309 |
| Total debt | 20,766 | 22,388 | 21,616 | 20,851 |
| Total liabilities | 25,426 | 27,432 | 26,845 | 25,989 |
| -692 | -1,022 | -1,279 | -554 | |
| 363 | 365 | 354 | 374 | |
| 5.3% | 3.5% | 6.0% | 7.7% | |
| 32.5% | 57.9% | 3.6% | -28.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -728 | 1,032 | 1,597 | 1,400 | |
| 268 | 272 | 340 | 407 | |
| -996 | 760 | 1,257 | 993 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 126 | 132 | 150 | 216 |
Valuation
- 19.7×
- 1.9×
- –
- -1.0×
- 0.3×
- 3.1×
- 7.1×
- 32.2%
- 5.1%
- 0.0%
Profitability
- 70.7%
- 21.3%
- 1.5%
- 34.3%
- 11.6%
- -1.5%
- 120.7%
- -4.9%
- 12.1%
- 6.2%
Growth
- +8.1%
- –
- −20.4%
- –
- +0.8%
Financial health
- 5.4×
- -10.10
- 84.9%
- 1.4×
- 1.32
- 0.97
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 24%of 952
Top 21%of 883
Top 33%of 576
Bottom 39%of 870
Top 2%of 985
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.78 | 0.81 | −3.7% |
| Feb 18, 2026 | 1.08 | 1.21 | −10.7% |
| Oct 29, 2025 | 1.16 | 1.07 | +8.4% |
| Jul 30, 2025 | 0.90 | 0.97 | −7.2% |
| Apr 30, 2025 | 0.59 | 0.83 | −28.9% |
| Feb 19, 2025 | 1.15 | 1.65 | −30.3% |
| Oct 30, 2024 | 1.12 | 1.03 | +8.7% |
| Aug 1, 2024 | 0.89 | 0.88 | +1.1% |
News
Bausch + Lomb Corporation Q3 2026 Earnings Call SummaryYahoo Finance · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
38No pass
Philip Fisher
47No pass
Peter Lynch
30No pass
Joel Greenblatt
42No pass
Charlie Munger
40No pass
Terry Smith
43No pass
Questions about Bausch Health Companies
Is Bausch Health Companies a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bausch Health Companies AI analysis
What does Bausch Health Companies do?
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It is in Drug Manufacturers - Specialty & Generic.
Does Bausch Health Companies pay a dividend?
No. Bausch Health Companies does not pay a dividend at the moment.
Is Bausch Health Companies stock halal?
No. Bausch Health Companies does not pass our halal screen: its debt is 675% of its market value, at or above the 33% limit. How we check
How has Bausch Health Companies stock done over the past year?
Up 18.9% over the past twelve months, to $8.25. It traded between $4.43 and $8.91 and is 7.4% below its high.
Who are Bausch Health Companies's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Bausch Health Companies's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.